Adial Pharmaceuticals, Inc.: adjourns votes at 2026 annual meeting

What happened

• Adial Pharmaceuticals, Inc. filed an 8-K on Oct 16, 2026 reporting that on Sep 17, 2026 it convened its 2026 Annual Meeting but, because it had not received Nasdaq’s conditional approval of its Initial Listing Application, it proceeded only with votes on Proposals 1, 2, 7, 8, 9, 10, 11 and 12 and adjourned votes on Proposals 3, 4, 5 and 6.
• The Company reconvened the meeting for Proposals 3, 4, 5 and 6 on Oct 1, 2026 and again adjourned those proposals until Oct 15, 2026; it reconvened on Oct 15, 2026 and again adjourned the votes. The polls remain open for Proposals 3, 4, 5 and 6.

Key details

• The adjourned meeting will reconvene on Oct 26, 2026 at 8:30 a.m. Eastern Time at 650 Peter Jefferson Parkway, Suite 230, Charlottesville, Virginia 22911.
• The record date for the 2026 Annual Meeting, as further adjourned, remains Aug 17, 2026.
• The Definitive Proxy Statement for the 2026 Annual Meeting was filed with the SEC on Aug 24, 2026 and has been mailed to stockholders entitled to vote.
• Stockholders who already submitted proxies with votes on Proposals 3, 4, 5 and 6 do not need to take further action unless they wish to change their vote.

Why it may matter

• Item reported: Item 8.01 (Other events). Item 8.01 covers events the company reported outside the other specified 8-K items, here describing the adjournments and reconvenings of the 2026 Annual Meeting and the pending Nasdaq approval of the Initial Listing Application.
• The filing states that the Company and its directors and executive officers and other employees may be participants in the solicitation of proxies and that the Definitive Proxy Statement and other materials are available free at the SEC’s website at www.sec.gov.

The filing does not show why the company acted.